PNC Financial Services Group’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $139K | Sell |
15,566
-333
| -2% | -$2.98K | ﹤0.01% | 2467 |
|
|
2025
Q1 | $119K | Sell |
15,899
-1,337
| -8% | -$10K | ﹤0.01% | 2550 |
|
|
2024
Q4 | $130K | Sell |
17,236
-997
| -5% | -$7.5K | ﹤0.01% | 2506 |
|
|
2024
Q3 | $139K | Buy |
18,233
+349
| +2% | +$2.65K | ﹤0.01% | 2461 |
|
|
2024
Q2 | $111K | Buy |
17,884
+424
| +2% | +$2.62K | ﹤0.01% | 2568 |
|
|
2024
Q1 | $88.7K | Buy |
17,460
+6,533
| +60% | +$33.2K | ﹤0.01% | 2677 |
|
|
2023
Q4 | $65.5K | Sell |
10,927
-990
| -8% | -$5.93K | ﹤0.01% | 2831 |
|
|
2023
Q3 | $84.4K | Sell |
11,917
-6,018
| -34% | -$42.6K | ﹤0.01% | 2674 |
|
|
2023
Q2 | $126K | Buy |
17,935
+2,688
| +18% | +$18.9K | ﹤0.01% | 2497 |
|
|
2023
Q1 | $127K | Buy |
15,247
+3,027
| +25% | +$25.2K | ﹤0.01% | 2418 |
|
|
2022
Q4 | $140K | Buy |
12,220
+2,520
| +26% | +$28.9K | ﹤0.01% | 2354 |
|
|
2022
Q3 | $122K | Buy |
9,700
+4,917
| +103% | +$61.8K | ﹤0.01% | 2398 |
|
|
2022
Q2 | $51K | Buy |
4,783
+1,111
| +30% | +$11.8K | ﹤0.01% | 2979 |
|
|
2022
Q1 | $59K | Sell |
3,672
-1,506
| -29% | -$24.2K | ﹤0.01% | 3002 |
|
|
2021
Q4 | $71K | Buy |
5,178
+5,089
| +5,718% | +$69.8K | ﹤0.01% | 2897 |
|
|
2021
Q3 | $1K | Hold |
89
| – | – | ﹤0.01% | 4173 |
|
|
2021
Q2 | $1K | Hold |
89
| – | – | ﹤0.01% | 4092 |
|
|
2021
Q1 | $1K | Buy |
+89
| New | +$1K | ﹤0.01% | 4012 |
|
|
2018
Q1 | – | Sell |
-103
| Closed | -$1K | – | 4174 |
|
|
2017
Q4 | $1K | Buy |
+103
| New | +$1K | ﹤0.01% | 4072 |
|
|
2016
Q3 | – | Sell |
-301
| Closed | -$1K | – | 3989 |
|
|
2016
Q2 | $1K | Sell |
301
-12
| -4% | -$40 | ﹤0.01% | 4334 |
|
|
2016
Q1 | $1K | Buy |
313
+198
| +172% | +$633 | ﹤0.01% | 4345 |
|
|
2015
Q4 | $1K | Buy |
+115
| New | +$1K | ﹤0.01% | 4307 |
|